Brief: LumiraDx Ltd Announces FDA EUA Submission For Its SARS-COV-2 & Flu A/B Rapid Antigen Test
15/10/2021 13:21
Oct 15 (Reuters) - LumiraDx Ltd LMDX.O :
* LUMIRADX ANNOUNCES FDA EUA SUBMISSION FOR ITS SARS-COV-2 &
FLU
A/B RAPID ANTIGEN TEST
Source text for Eikon: ID:nPn8Czf7Ba
Further company coverage: LMDX.O
Recent news on LumiraDx
See all newsBrief: LumiraDx Announces Its Securities Will Be Suspended From Trading On Nasdaq At The Open Of Business On January 9Th
Roche to buy part of LumiraDx diagnostics platform for $295 million
Brief: LumiraDx- Under Terms Of Certain Loan Agreement, Dated March 23, 2021, The Waiver Period Has Expired As Of Today
Brief: LumiraDx Announces Agreement to Sell its Cutting Edge Point of Care Technology Platform to Roche
Brief: Willard L. Umphrey Reports 10.31% Stake In Lumiradx Limited As Of Dec 22- SEC Filing